In-line pharma monitoring system developed for tablet quality inspection
The novel approach could enhance quality testing applications in pharmaceutical manufacturing.
List view / Grid view
The novel approach could enhance quality testing applications in pharmaceutical manufacturing.
The innovation is set to change how eligible bladder cancer patients in the US are treated who are unresponsive to traditional therapy.
The regulator’s new principles aim to ease the pathway to regulatory approval for rare disease drug developers in the US.
CE mark for Contivue platform supports its ambitions for Susvimo in age-related macular degeneration (AMD).
The new Thousand Oaks, California facility will incorporate advanced automation and digital capabilities.
David Weinreich will also serve as its Chief Medical Officer and arrives at the German pharmaceutical group with experience from Amgen, Bayer and Regeneron.
Significant investment in advanced technologies Is expected to support global adoption of mass spectrometry in the next five years.
First-of-its-kind case continues EMA and MHRA harmonisation, streamlining the global biosimilar approval pathway.
2 September 2025 | By FUJIFILM Wako Europe GmbH
Join this webinar to find out how RT-rt PCR is revolutionising sterility testing and discover a unique approach that provides reliable one-day results and enhanced sensitivity and detection capabilities.
While AstraZeneca’s first-in-class candidate baxdrostat marks phase III hypertension win at ESC 2025.
And Eli Lilly and Company’s new oral GLP-1 obesity therapy orforglipron shines in late-phase clinical trials.
The Route B notification pilot will expand the MHRA’s risk-proportionate approach and help prepare for a new modifications process under upcoming regulations.
The paper explores recent guidance by the EMA and aims to help companies ensure their developments are efficient and effective for the forthcoming transition.
Further to its potential in Stargardt disease, if approved, the one-time gene therapy could become standard of care for retinitis pigmentosa, alongside other retinal degenerative diseases.
Becomes the first monoclonal antibody for the condition to be approved by the MHRA and advances the pharma company’s ambitions in diabetes.